These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1138 related articles for article (PubMed ID: 26840595)
1. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595 [TBL] [Abstract][Full Text] [Related]
2. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study. Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853 [TBL] [Abstract][Full Text] [Related]
3. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647 [TBL] [Abstract][Full Text] [Related]
4. Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Dimitrow PP; Klimeczek P; Vliegenthart R; Pasowicz M; Oudkerk M; Podolec P; Tracz W; Dubiel JS Int J Cardiovasc Imaging; 2008 Jan; 24(1):77-83; discussion 85-7. PubMed ID: 17624806 [TBL] [Abstract][Full Text] [Related]
5. Prognostic role of CMR in patients presenting with ventricular arrhythmias. Dawson DK; Hawlisch K; Prescott G; Roussin I; Di Pietro E; Deac M; Wong J; Frenneaux MP; Pennell DJ; Prasad SK JACC Cardiovasc Imaging; 2013 Mar; 6(3):335-44. PubMed ID: 23433931 [TBL] [Abstract][Full Text] [Related]
6. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820 [TBL] [Abstract][Full Text] [Related]
7. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435 [TBL] [Abstract][Full Text] [Related]
8. High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Hen Y; Iguchi N; Machida H; Takada K; Utanohara Y; Sumiyoshi T Heart Vessels; 2013 Nov; 28(6):742-9. PubMed ID: 23097076 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044 [TBL] [Abstract][Full Text] [Related]
10. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875 [TBL] [Abstract][Full Text] [Related]
11. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699 [TBL] [Abstract][Full Text] [Related]
12. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention. Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967 [TBL] [Abstract][Full Text] [Related]
13. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Perazzolo Marra M; De Lazzari M; Zorzi A; Migliore F; Zilio F; Calore C; Vettor G; Tona F; Tarantini G; Cacciavillani L; Corbetti F; Giorgi B; Miotto D; Thiene G; Basso C; Iliceto S; Corrado D Heart Rhythm; 2014 May; 11(5):856-63. PubMed ID: 24440822 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: correlation with nonsustained ventricular tachycardia. Correia E; Rodrigues B; Santos LF; Moreira D; Gama P; Cabral C; Santos O Echocardiography; 2011 Aug; 28(7):709-14. PubMed ID: 21564281 [TBL] [Abstract][Full Text] [Related]
15. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307 [TBL] [Abstract][Full Text] [Related]
16. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients. Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597 [TBL] [Abstract][Full Text] [Related]
17. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis. Nakamura T; Iwanaga Y; Yasuda M; Kawamura T; Miyaji Y; Morooka H; Miyazaki S Int J Cardiovasc Imaging; 2016 Apr; 32(4):613-20. PubMed ID: 26589516 [TBL] [Abstract][Full Text] [Related]
18. Late gadolinium enhancement of cardiac magnetic resonance imaging indicates abnormalities of time-domain T-wave alternans in hypertrophic cardiomyopathy with ventricular tachycardia. Sakamoto N; Sato N; Oikawa K; Karim Talib A; Sugiyama E; Minoshima A; Tanabe Y; Takeuchi T; Akasaka K; Saijo Y; Kawamura Y; Hasebe N Heart Rhythm; 2015 Aug; 12(8):1747-55. PubMed ID: 25916568 [TBL] [Abstract][Full Text] [Related]
19. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. Bongioanni S; Spirito P; Masi AS; Chiribiri A; Bonamini R; Conte MR Circ Cardiovasc Imaging; 2009 Jul; 2(4):349-50. PubMed ID: 19808616 [No Abstract] [Full Text] [Related]
20. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. He D; Ye M; Zhang L; Jiang B Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]